Orbus Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 1
- Market Cap
- -
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Orbus Therapeutics, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT05879367
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸The Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸UT MD Anderson Cancer Center, Houston, Texas, United States
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Orbus Therapeutics, Inc.
- Target Recruit Count
- 343
- Registration Number
- NCT02796261
- Locations
- 🇨🇦
Montreal Neurological Institute and Hospital, Montréal, Quebec, Canada
🇫🇷Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷Centre Georges François Leclerc, Dijon, France
© Copyright 2024. All Rights Reserved by MedPath